The Discovery of CDP323, a Potent Alpha4 Integrin Antagonist

Author(s): Stuart Bailey, Roger Palframan, Gillian Watt, John Porter

Journal Name: Current Immunology Reviews (Discontinued)

Volume 8 , Issue 2 , 2012


Blocking the action of alpha4 integrin would be expected to be of therapeutic benefit in the management of autoimmune diseases. Although this has been successfully demonstrated in the clinic with a monoclonal antibody for the treatment of multiple sclerosis, there are no small molecule alpha4 integrin antagonists on the market despite significant endeavour over the last 15-20 years. We review our efforts in this area, starting from a cyclic peptide based on an integrin recognition sequence and culminating in the low molecular weight clinical candidate, CDP323. We include a discussion on pre-clinical pharmacological data for CDP323.

Keywords: Alpha4 integrin, CDP323, integrin antagonists, VLA-4 integrin

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 21 March, 2012
Page: [135 - 140]
Pages: 6
DOI: 10.2174/157339512800099675
Price: $65

Article Metrics

PDF: 7